MET and neoplasm: Although the current clinical trials targeting cMET are conducted mostly in combination with other kinase inhibitors making it hard to interpret the sole efficacy of cMET inhibition, collectively, these data suggest that cMET inhibitors are safe and can show anti-tumor activity in mUM patients.